Collecting data and samples from colorectal cancer patients for precision research

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ALFAOMEGA-RETRÒ is designed to retrospectively gather clinical and imaging data, along with biological samples from colorectal cancer patients. This observational study aims to create a repository that will support precision research by validating and correlating findings from ongoing translational projects. The collected data will help define a new taxonomy of colorectal cancer based on evolutionary patterns and develop innovative biomarker-specific therapeutic strategies. The study will utilize various clinical and imaging data, as well as formalin-fixed and frozen biological samples.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-confirmed diagnosis of colorectal cancer (any stage).
* Age \>18 years at the time of diagnosis.
* Availability of clinically-annotated radio-imaging data and/or diagnostic Formalin-Fixed Paraffin Embedded (FFPE) blocks (surgical resections and/or tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.
* Verification that the patient could not be reached for informed consent in accordance with applicable national regulations.

Exclusion Criteria:

* if inclusion criteria are not met

Where it's running

• Ospedale Policlinico San Martino
  Genova, Ge, Italy Recruiting
• Fondazione IRCCS, Istituto Nazionale dei Tumori
  Milan, Mi, Italy Recruiting
• Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda
  Milan, Mi, Italy Recruiting
• IRCCS Istituto Clinico Humanitas
  Milan, Mi, Italy Recruiting
• Istituto Oncologico Veneto (IOV)
  Padua, Pd, Italy Recruiting
• Azienda Ospedaliero Universitaria Pisana
  Pisa, Pisa, Italy Recruiting

Study contacts

• Study coordinator: Luca Lazzari, PhD
• Email: clinical.trials@ifom.eu
• Phone: +3902574303799

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.